Immuneering Raises $25M in Private Placement for Cancer Treatment Development

Immuneering Corporation has raised $25 million in a private placement of securities from institutional and accredited investors. The funds will support the development of atebimetinib, a Deep Cyclic Inhibitor of MEK in the MAPK pathway, for cancer patients. The company plans to announce updated Overall Survival and Progression-Free Survival data from its Phase 2a trial in the coming weeks, with exceptional 6-month overall survival data in first-line pancreatic cancer patients.

Immuneering Corporation, a clinical-stage oncology company, has successfully raised $25 million in a private placement of securities from institutional and accredited investors. The funds will be dedicated to the development of atebimetinib, a Deep Cyclic Inhibitor of MEK in the MAPK pathway, for cancer patients.

The company's lead product candidate, atebimetinib, has shown promising results in its Phase 2a trial. The trial demonstrated a 94% overall survival (OS) rate at 6 months in first-line pancreatic cancer patients, surpassing the historical standard of care regimen's 67% OS rate at six months [1]. Additionally, the trial reported a 72% progression-free survival (PFS) rate at six months.

Immuneering Corporation has also received a U.S. composition of matter patent for atebimetinib, providing exclusivity until 2042. The company has submitted a request for an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA), with plans to initiate a Phase 3 pivotal trial in 2026 [1].

The company's financial results for the second quarter ended June 30, 2025, showed a net loss of $14.4 million, or $0.40 per share, which exceeded the analyst estimate of -$0.42 per share. The company's cash balance stood at $26.4 million as of June 30, 2025, with a projected runway into 2026 [1].

The new funding will support the company's near-term milestones, including the announcement of updated OS and PFS data from first-line pancreatic cancer patients (n = 34) treated with atebimetinib + mGnP in Q3 2025, and the initiation of a pivotal, randomized trial of atebimetinib in combination with mGnP in first-line pancreatic cancer in 2026 [2].

References:
[1] https://www.ainvest.com/news/immuneering-corp-q2-2025-earnings-eps-beats-estimate-reports-14-4m-net-loss-highlights-robust-cash-position-clinical-advancements-2508/
[2] https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-second-quarter-2025-financial-results-and